Commercial J&J sets the tone for Q1 earnings with strong oncology growth Pharmaceutical TechnologyOff the back of J J's positive Q1, CEO Joaquin Duato forecasts strong growth acceleration for 2026, driven partially by psoriasis med IcotydeCommercialOncologyRead full story pharminent April 15, 2026 Pharmaceutical Technology Off the back of J J’s positive Q1, CEO Joaquin Duato forecasts strong growth acceleration for 2026, driven partially by psoriasis med Icotyde CommercialOncologyRead full story Post navigation Previous: Amazon launches its AI drug discovery platformNext: Adcendo secures $75m in Series C funding for ADC development Related Stories Commercial Novo’s CEO champions “record-breaking start” for Wegovy pill in US market pharminent May 8, 2026 Commercial Novo hikes guidance on Wegovy pill’s fast sales start pharminent May 6, 2026 Commercial Novo’s Wegovy pill reaches 1M patients, shattering expectations with $355M in sales pharminent May 6, 2026
